David Lewis
Stock Analyst at Morgan Stanley
(2.72)
# 2,098
Out of 5,014 analysts
271
Total ratings
67.18%
Success rate
9.44%
Average return
Main Sectors:
Stocks Rated by David Lewis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Equal-Weight | $127 → $137 | $132.21 | +3.62% | 25 | Jul 15, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $273 → $300 | $315.00 | -4.76% | 22 | Nov 4, 2022 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $272 → $275 | $186.42 | +47.52% | 23 | Oct 11, 2022 | |
| DXCM DexCom | Maintains: Equal-Weight | $91 → $91 | $65.49 | +38.95% | 21 | Jun 15, 2022 | |
| OM Outset Medical | Maintains: Overweight | $750 → $720 | $12.64 | +5,596.20% | 6 | May 5, 2022 | |
| BAX Baxter International | Maintains: Overweight | $105 → $100 | $21.65 | +361.89% | 14 | Apr 29, 2022 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $22 → $15 | $108.50 | -86.18% | 7 | Feb 25, 2022 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $37 → $30 | $1.60 | +1,780.88% | 6 | Feb 25, 2022 | |
| HOLX Hologic | Maintains: Equal-Weight | $76 → $75 | $67.39 | +11.29% | 11 | Feb 3, 2022 | |
| NVST Envista Holdings | Maintains: Equal-Weight | $42 → $45 | $19.06 | +136.10% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $60 | $48.31 | +24.21% | 12 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $82 | $57.00 | +43.86% | 5 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $478 → $431 | $119.09 | +261.91% | 10 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $154 | $95.46 | +61.32% | 17 | Aug 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $40 | $15.09 | +165.08% | 8 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $108 → $135 | $74.25 | +81.82% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $265 → $280 | $367.85 | -23.88% | 9 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $260 → $285 | $433.02 | -34.18% | 13 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $6.46 | +194.12% | 2 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $288 → $94 | $177.82 | -47.14% | 8 | Apr 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $79 | $71.69 | +10.20% | 7 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $180 | $95.00 | +89.47% | 14 | Feb 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $187 | $190.27 | -1.72% | 11 | Jan 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $45 | $10.70 | +320.56% | 5 | Dec 15, 2020 |
Abbott Laboratories
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $127 → $137
Current: $132.21
Upside: +3.62%
Insulet
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $273 → $300
Current: $315.00
Upside: -4.76%
Becton, Dickinson and Company
Oct 11, 2022
Maintains: Overweight
Price Target: $272 → $275
Current: $186.42
Upside: +47.52%
DexCom
Jun 15, 2022
Maintains: Equal-Weight
Price Target: $91 → $91
Current: $65.49
Upside: +38.95%
Outset Medical
May 5, 2022
Maintains: Overweight
Price Target: $750 → $720
Current: $12.64
Upside: +5,596.20%
Baxter International
Apr 29, 2022
Maintains: Overweight
Price Target: $105 → $100
Current: $21.65
Upside: +361.89%
TransMedics Group
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $22 → $15
Current: $108.50
Upside: -86.18%
Pulmonx
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $37 → $30
Current: $1.60
Upside: +1,780.88%
Hologic
Feb 3, 2022
Maintains: Equal-Weight
Price Target: $76 → $75
Current: $67.39
Upside: +11.29%
Envista Holdings
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $42 → $45
Current: $19.06
Upside: +136.10%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $68 → $60
Current: $48.31
Upside: +24.21%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $80 → $82
Current: $57.00
Upside: +43.86%
Oct 29, 2021
Maintains: Overweight
Price Target: $478 → $431
Current: $119.09
Upside: +261.91%
Aug 25, 2021
Maintains: Overweight
Price Target: $140 → $154
Current: $95.46
Upside: +61.32%
Aug 3, 2021
Maintains: Overweight
Price Target: $41 → $40
Current: $15.09
Upside: +165.08%
Jul 30, 2021
Maintains: Overweight
Price Target: $108 → $135
Current: $74.25
Upside: +81.82%
Apr 28, 2021
Maintains: Overweight
Price Target: $265 → $280
Current: $367.85
Upside: -23.88%
Apr 21, 2021
Maintains: Equal-Weight
Price Target: $260 → $285
Current: $433.02
Upside: -34.18%
Apr 19, 2021
Maintains: Overweight
Price Target: $18 → $19
Current: $6.46
Upside: +194.12%
Apr 14, 2021
Downgrades: Equal-Weight
Price Target: $288 → $94
Current: $177.82
Upside: -47.14%
Feb 25, 2021
Maintains: Overweight
Price Target: $75 → $79
Current: $71.69
Upside: +10.20%
Feb 8, 2021
Maintains: Overweight
Price Target: $170 → $180
Current: $95.00
Upside: +89.47%
Jan 27, 2021
Maintains: Overweight
Price Target: $178 → $187
Current: $190.27
Upside: -1.72%
Dec 15, 2020
Maintains: Underweight
Price Target: $36 → $45
Current: $10.70
Upside: +320.56%